343 related articles for article (PubMed ID: 31916060)
1. Investigation of genetic base in the treatment of age-related macular degeneration.
Gourgouli K; Gourgouli I; Tsaousis G; Spai S; Niskopoulou M; Efthimiopoulos S; Lamnissou K
Int Ophthalmol; 2020 Apr; 40(4):985-997. PubMed ID: 31916060
[TBL] [Abstract][Full Text] [Related]
2. Association of Single-Nucleotide Polymorphisms in Age-Related Macular Degeneration With Pseudodrusen: Secondary Analysis of Data From the Comparison of AMD Treatments Trials.
Lin LY; Zhou Q; Hagstrom S; Maguire MG; Daniel E; Grunwald JE; Martin DF; Ying GS;
JAMA Ophthalmol; 2018 Jun; 136(6):682-688. PubMed ID: 29801032
[TBL] [Abstract][Full Text] [Related]
3. Genetic influences on the outcome of anti-vascular endothelial growth factor treatment in neovascular age-related macular degeneration.
Abedi F; Wickremasinghe S; Richardson AJ; Islam AF; Guymer RH; Baird PN
Ophthalmology; 2013 Aug; 120(8):1641-8. PubMed ID: 23582991
[TBL] [Abstract][Full Text] [Related]
4. Single-Nucleotide Polymorphisms Associated With Age-Related Macular Degeneration and Lesion Phenotypes in the Comparison of Age-Related Macular Degeneration Treatments Trials.
Maguire MG; Ying GS; Jaffe GJ; Toth CA; Daniel E; Grunwald J; Martin DF; Hagstrom SA;
JAMA Ophthalmol; 2016 Jun; 134(6):674-81. PubMed ID: 27099955
[TBL] [Abstract][Full Text] [Related]
5. Cumulative effect of risk alleles in CFH, ARMS2, and VEGFA on the response to ranibizumab treatment in age-related macular degeneration.
Smailhodzic D; Muether PS; Chen J; Kwestro A; Zhang AY; Omar A; Van de Ven JP; Keunen JE; Kirchhof B; Hoyng CB; Klevering BJ; Koenekoop RK; Fauser S; den Hollander AI
Ophthalmology; 2012 Nov; 119(11):2304-11. PubMed ID: 22840423
[TBL] [Abstract][Full Text] [Related]
6. Association between CFH, CFB, ARMS2, SERPINF1, VEGFR1 and VEGF polymorphisms and anatomical and functional response to ranibizumab treatment in neovascular age-related macular degeneration.
Cobos E; Recalde S; Anter J; Hernandez-Sanchez M; Barreales C; Olavarrieta L; Valverde A; Suarez-Figueroa M; Cruz F; Abraldes M; Pérez-Pérez J; Fernández-Robredo P; Arias L; García-Layana A
Acta Ophthalmol; 2018 Mar; 96(2):e201-e212. PubMed ID: 28926193
[TBL] [Abstract][Full Text] [Related]
7. ARMS2 A69S polymorphism is associated with the number of ranibizumab injections needed for exudative age-related macular degeneration in a pro re nata regimen during 4 years of follow-up.
Valverde-Megías A; Veganzones-de-Castro S; Donate-López J; Maestro-de-Las-Casas ML; Megías-Fresno A; García-Feijoo J
Graefes Arch Clin Exp Ophthalmol; 2017 Nov; 255(11):2091-2098. PubMed ID: 28744656
[TBL] [Abstract][Full Text] [Related]
8. Effects of aflibercept for ranibizumab-resistant neovascular age-related macular degeneration and polypoidal choroidal vasculopathy.
Kawashima Y; Oishi A; Tsujikawa A; Yamashiro K; Miyake M; Ueda-Arakawa N; Yoshikawa M; Takahashi A; Yoshimura N
Graefes Arch Clin Exp Ophthalmol; 2015 Sep; 253(9):1471-7. PubMed ID: 25391986
[TBL] [Abstract][Full Text] [Related]
9. Complement factor H Y402H gene polymorphism and response to intravitreal bevacizumab in exudative age-related macular degeneration.
Nischler C; Oberkofler H; Ortner C; Paikl D; Riha W; Lang N; Patsch W; Egger SF
Acta Ophthalmol; 2011 Jun; 89(4):e344-9. PubMed ID: 21232084
[TBL] [Abstract][Full Text] [Related]
10. GENETICS OF LARGE PIGMENT EPITHELIAL DETACHMENTS IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
Mouallem-Beziere A; Blanco-Garavito R; Richard F; Miere A; Jung C; Rozet JM; Souied EH
Retina; 2020 Apr; 40(4):663-671. PubMed ID: 30681643
[TBL] [Abstract][Full Text] [Related]
11. Genetic Variants of Complement Factor H Y402H (rs1061170), C2 R102G (rs2230199), and C3 E318D (rs9332739) and Response to Intravitreal Anti-VEGF Treatment in Patients with Exudative Age-Related Macular Degeneration.
Kubicka-Trząska A; Żuber-Łaskawiec K; Dziedzina S; Sanak M; Romanowska-Dixon B; Karska-Basta I
Medicina (Kaunas); 2022 May; 58(5):. PubMed ID: 35630075
[No Abstract] [Full Text] [Related]
12. Comparison of ARMS2/LOC387715 A69S and CFH Y402H risk effect in wet-type age-related macular degeneration: a meta-analysis.
Jabbarpoor Bonyadi MH; Yaseri M; Nikkhah H; Bonyadi M; Nazari R; Soheilian M
Int Ophthalmol; 2019 Apr; 39(4):949-956. PubMed ID: 29423786
[TBL] [Abstract][Full Text] [Related]
13. [Association between Y402H, E318D and R102G polymorphisms of complement proteins genes and the response to intravitreal anti-VEGF treatment in patients with neovascular age-related macular degeneration].
Kubicka-Trząska A; Karska-Basta I; Kobylarz J; Dziedzina S; Sanak M; Romanowska-Dixon B
Klin Oczna; 2016; 118(2):114-21. PubMed ID: 29912491
[TBL] [Abstract][Full Text] [Related]
14. Association of the CFH Y402H Polymorphism with the 1-Year Response of Exudative AMD to Intravitreal Anti-VEGF Treatment in the Brazilian Population.
Medina FMC; Motta AALD; Takahashi WY; Carricondo PC; Motta MMDS; Melo MB; Vasconcellos JPC
Ophthalmic Res; 2019; 61(3):168-173. PubMed ID: 28641277
[TBL] [Abstract][Full Text] [Related]
15. Factors associated with the response of age-related macular degeneration to intravitreal ranibizumab treatment.
Yamashiro K; Tomita K; Tsujikawa A; Nakata I; Akagi-Kurashige Y; Miyake M; Ooto S; Tamura H; Yoshimura N
Am J Ophthalmol; 2012 Jul; 154(1):125-36. PubMed ID: 22465368
[TBL] [Abstract][Full Text] [Related]
16. Pharmacogenetics for genes associated with age-related macular degeneration in the Comparison of AMD Treatments Trials (CATT).
Hagstrom SA; Ying GS; Pauer GJT; Sturgill-Short GM; Huang J; Callanan DG; Kim IK; Klein ML; Maguire MG; Martin DF;
Ophthalmology; 2013 Mar; 120(3):593-599. PubMed ID: 23337555
[TBL] [Abstract][Full Text] [Related]
17. Genetic Variants Affecting Anti-VEGF Drug Response in Polypoidal Choroidal Vasculopathy Patients: A Systematic Review and Meta-Analysis.
Díaz-Villamarín X; Blánquez-Martínez D; Pozo-Agundo A; Pérez-Gutiérrez AM; Muñoz-Ávila JI; Antúnez-Rodríguez A; Fernández-Gómez AE; García-Navas P; Martínez-González LJ; Dávila-Fajardo CL
Genes (Basel); 2020 Nov; 11(11):. PubMed ID: 33198211
[TBL] [Abstract][Full Text] [Related]
18. Association of Smoking and CFH and ARMS2 Risk Variants With Younger Age at Onset of Neovascular Age-Related Macular Degeneration.
Lechanteur YT; van de Camp PL; Smailhodzic D; van de Ven JP; Buitendijk GH; Klaver CC; Groenewoud JM; den Hollander AI; Hoyng CB; Klevering BJ
JAMA Ophthalmol; 2015 May; 133(5):533-41. PubMed ID: 25695752
[TBL] [Abstract][Full Text] [Related]
19. Role of complement factor B rs4151667 (L9H) polymorphisms and its interactional role with CFH Y402H and C3 rs2230199 (R102G) risk variants in age-related macular degeneration: a case control study.
Roshanipour N; Laleh MG; Bonyadi M; Bonyadi MHJ; Soheilian M; Javadzadeh A; Yaseri M
BMC Ophthalmol; 2020 Aug; 20(1):323. PubMed ID: 32762675
[TBL] [Abstract][Full Text] [Related]
20. CFH Y402H and VEGF Polymorphisms and Anti-VEGF Treatment Response in Exudative Age-Related Macular Degeneration.
Kepez Yildiz B; Ozdek S; Ergun MA; Ergun S; Yaylacioglu Tuncay F; Elbeg S
Ophthalmic Res; 2016; 56(3):132-8. PubMed ID: 27404493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
